---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-316063"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:36:07.899090+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants

## Summary
- Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.
- Maximum leverage ratio set at 4.25x for Q4 2025 and thereafter; can increase 0.5x for acquisitions over $250M.
- Covenants suspended if Teva achieves Investment Grade Status (Baa3/BBB- from two agencies); reinstated on loss or default.
- Consent fee of 0.08% of total commitments paid to lenders approving the amendment.

## SEC filing metadata
- accession: 0001193125-25-316063
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312525316063/0001193125-25-316063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312525316063/d46386d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-316063
- JSON: https://secwatch.observer/filing/0001193125-25-316063.json
- Plain text: https://secwatch.observer/filing/0001193125-25-316063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.